Skip to main content

Table 3 The pharmacokinetic exposure parameters of plasma chiauranib after single and multiple dose of 10, 20, 35, 50, and 65 mg chiauranib capsules in patients with advanced solid tumor

From: Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors

  Tmax (h) AUC0–24 h (ng h/mL) AUC0–144 h (ng h/mL) Cmax (ng/mL) DF Ctrough (ng/mL) Cav (ng/mL)
Day1 10 mg (n = 2) 2.0 1998 3576 201 / / /
20 mg (n = 6) 2.0 (1–4) 3454 (1275) 6815 (3902) 354 (158) / / /
35 mg (n = 3) 1.0 (1–8) 5762 (3853) 11859 (8656) 608 (437) / / /
50 mg (n = 3) 1.0 (1–2) 7417 (1380) 16429 (5251) 756 (87) / / /
65 mg (n = 4) 1.5 (1–2) 11015 (3572) 24823 (12581) 1275 (358) / / /
Day28 10 mg (n = 2) 2.0 4185 / 312 1.1 (0.4) 122 (21) 174 (9)
20 mg (n = 6) 2.0 6175 (1526) / 517 (134) 1.3 (0.6) 191 (89) 257 (64)
35 mg (n = 3) 4 (1–4) 11761 (8066) / 773 (532) 0.8 (0.4) 330 (208) 490 (336)
50 mg (n = 3) 2 (1–2) 14504 (5650) / 1118 (254) 1.1 (0.3) 467 (166) 604 (235)
65 mg (n = 4) 2 (1–2) 24230 (11819) / 2238 (1012) 1.5 (0.8) 890 (662) 1010 (492)
  1. AUC0–24 h area under the concentration-time curve from 0 to 24 h, AUC 0–144 h area under the concentration-time curve from 0 to 144 h, Cmax maximum plasma concentration, Tmax time to reach maximum plasma concentration